Advaxis, Inc. (ADXS)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -36.26 Million USD | -125.39% |
| 2022 | -16.09 Million USD | 14.35% |
| 2021 | -18.78 Million USD | 28.97% |
| 2020 | -26.44 Million USD | -49.34% |
| 2019 | -17.71 Million USD | 74.83% |
| 2018 | -70.37 Million USD | 28.57% |
| 2017 | -98.52 Million USD | -28.81% |
| 2016 | -76.49 Million USD | -57.16% |
| 2015 | -48.67 Million USD | -149.1% |
| 2014 | -19.53 Million USD | -32.97% |
| 2013 | -14.69 Million USD | -19.12% |
| 2012 | -12.33 Million USD | 5.25% |
| 2011 | -13.01 Million USD | -64.25% |
| 2010 | -7.92 Million USD | -58.93% |
| 2009 | -4.98 Million USD | 8.53% |
| 2008 | -5.45 Million USD | -18.44% |
| 2007 | -4.6 Million USD | -50.95% |
| 2006 | -3.04 Million USD | -65.5% |
| 2005 | -1.84 Million USD | -245.09% |
| 2004 | -533.9 Thousand USD | -5239.04% |
| 2003 | -10 Thousand USD | 0.0% |
| 2002 | -10 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q3 | -7.13 Million USD | 15.97% |
| 2023 Q4 | -8.78 Million USD | -23.12% |
| 2023 FY | -36.26 Million USD | -125.39% |
| 2023 Q1 | -11.86 Million USD | -22.01% |
| 2023 Q2 | -8.48 Million USD | 28.5% |
| 2022 Q1 | -3 Million USD | 27.91% |
| 2022 Q2 | -7.29 Million USD | -142.87% |
| 2022 FY | -16.09 Million USD | 14.35% |
| 2022 Q4 | -9.72 Million USD | -100.45% |
| 2022 Q3 | -4.85 Million USD | 33.44% |
| 2021 Q1 | -9.22 Million USD | 2.27% |
| 2021 Q3 | -4.45 Million USD | 58.16% |
| 2021 FY | -18.78 Million USD | 28.97% |
| 2021 Q4 | -4.16 Million USD | 6.62% |
| 2021 Q2 | -10.65 Million USD | -15.49% |
| 2020 Q2 | -6.61 Million USD | -2.7% |
| 2020 Q4 | -9.44 Million USD | -69.61% |
| 2020 FY | -26.44 Million USD | -49.34% |
| 2020 Q1 | -6.43 Million USD | -19.55% |
| 2020 Q3 | -5.56 Million USD | 15.82% |
| 2019 Q2 | -3.76 Million USD | -4.67% |
| 2019 Q1 | -3.6 Million USD | -134.9% |
| 2019 Q3 | -4.95 Million USD | -31.56% |
| 2019 FY | -17.71 Million USD | 74.83% |
| 2019 Q4 | -5.38 Million USD | -8.65% |
| 2018 Q3 | -22.11 Million USD | -56.14% |
| 2018 Q1 | -13.55 Million USD | 34.04% |
| 2018 FY | -70.37 Million USD | 28.57% |
| 2018 Q4 | 10.31 Million USD | 146.65% |
| 2018 Q2 | -14.16 Million USD | -4.51% |
| 2017 FY | -98.52 Million USD | -28.81% |
| 2017 Q1 | -20.66 Million USD | -20.24% |
| 2017 Q2 | -32.81 Million USD | -58.79% |
| 2017 Q4 | -20.54 Million USD | 26.27% |
| 2017 Q3 | -27.86 Million USD | 15.06% |
| 2016 Q2 | -16.56 Million USD | -6.24% |
| 2016 FY | -76.49 Million USD | -57.16% |
| 2016 Q4 | -17.18 Million USD | 29.51% |
| 2016 Q3 | -24.38 Million USD | -47.17% |
| 2016 Q1 | -15.59 Million USD | 21.85% |
| 2015 Q4 | -19.95 Million USD | -38.31% |
| 2015 FY | -48.67 Million USD | -149.1% |
| 2015 Q2 | -13.62 Million USD | 1.52% |
| 2015 Q3 | -14.42 Million USD | -5.84% |
| 2015 Q1 | -13.83 Million USD | -104.25% |
| 2014 Q4 | -6.77 Million USD | -35.91% |
| 2014 Q1 | -2.59 Million USD | 56.43% |
| 2014 FY | -19.53 Million USD | -32.97% |
| 2014 Q3 | -4.98 Million USD | 16.89% |
| 2014 Q2 | -5.99 Million USD | -131.09% |
| 2013 FY | -14.69 Million USD | -19.12% |
| 2013 Q4 | -5.95 Million USD | -49.61% |
| 2013 Q3 | -3.98 Million USD | -30.41% |
| 2013 Q1 | -5.47 Million USD | -151.11% |
| 2013 Q2 | -3.05 Million USD | 44.24% |
| 2012 Q3 | -2.27 Million USD | -163.56% |
| 2012 Q4 | -2.18 Million USD | 4.23% |
| 2012 FY | -12.33 Million USD | 5.25% |
| 2012 Q1 | -3.22 Million USD | 0.45% |
| 2012 Q2 | 3.58 Million USD | 210.94% |
| 2011 Q2 | -3.59 Million USD | -5.53% |
| 2011 FY | -13.01 Million USD | -64.25% |
| 2011 Q4 | -3.24 Million USD | -6.58% |
| 2011 Q1 | -3.4 Million USD | -14.77% |
| 2011 Q3 | -3.04 Million USD | 15.37% |
| 2010 Q2 | -1.8 Million USD | -1.31% |
| 2010 Q1 | -1.77 Million USD | -12.01% |
| 2010 Q3 | -2.76 Million USD | -53.49% |
| 2010 Q4 | -2.96 Million USD | -7.47% |
| 2010 FY | -7.92 Million USD | -58.93% |
| 2009 FY | -4.98 Million USD | 8.53% |
| 2009 Q4 | -1.58 Million USD | 21.57% |
| 2009 Q2 | -1.46 Million USD | -90.02% |
| 2009 Q1 | -772.28 Thousand USD | -6.58% |
| 2009 Q3 | -2.02 Million USD | -37.82% |
| 2008 Q2 | -1.23 Million USD | 23.72% |
| 2008 Q4 | -724.62 Thousand USD | 37.88% |
| 2008 Q3 | -1.16 Million USD | 5.52% |
| 2008 Q1 | -1.61 Million USD | -12.99% |
| 2008 FY | -5.45 Million USD | -18.44% |
| 2007 Q2 | -820.92 Thousand USD | 46.18% |
| 2007 Q3 | -1.06 Million USD | -29.58% |
| 2007 Q4 | -1.43 Million USD | -34.65% |
| 2007 FY | -4.6 Million USD | -50.95% |
| 2007 Q1 | -1.52 Million USD | -27.88% |
| 2006 Q4 | -1.19 Million USD | -31.91% |
| 2006 Q1 | -987.13 Thousand USD | -110.45% |
| 2006 FY | -3.04 Million USD | -65.5% |
| 2006 Q2 | -688.75 Thousand USD | 30.23% |
| 2006 Q3 | -904.31 Thousand USD | -31.3% |
| 2005 Q4 | -469.06 Thousand USD | 0.18% |
| 2005 Q3 | -469.92 Thousand USD | -16.01% |
| 2005 Q1 | -722.35 Thousand USD | -194.69% |
| 2005 FY | -1.84 Million USD | -245.09% |
| 2005 Q2 | -405.05 Thousand USD | 43.93% |
| 2004 Q4 | -245.12 Thousand USD | 0.0% |
| 2004 FY | -533.9 Thousand USD | -5239.04% |
| 2003 FY | -10 Thousand USD | 0.0% |
| 2002 FY | -10 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HST Global, Inc. | -140.9 Thousand USD | -25637.543% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -5179.278% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -21045.179% |
| CytoDyn Inc. | -18.05 Million USD | -100.831% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 38.522% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| MultiCell Technologies, Inc. | -722.81 USD | -5017262.792% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -1896.675% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -618.924% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -120980.395% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -19882.919% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Alpha Cognition Inc. | -9.7 Million USD | -273.661% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 34.665% |
| SQZ Biotechnologies Company | -75.82 Million USD | 52.171% |
| Resverlogix Corp. | -12.74 Million USD | -184.462% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -9209.238% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 472.247% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -1377.039% |
| Mesoblast Limited | -84.14 Million USD | 56.902% |
| GB Sciences, Inc. | -1.42 Million USD | -2453.029% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -5179.278% |
| Evofem Biosciences, Inc. | -17.84 Million USD | -103.205% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -965.087% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -445.516% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -1044.661% |
| ContraFect Corporation | -56.88 Million USD | 36.251% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -1218.361% |
| BioStem Technologies, Inc. | -7.77 Million USD | -366.206% |
| LadRx Corporation | -3.82 Million USD | -848.471% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -128.523% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -3140.929% |
| CSL Limited | 3.7 Billion USD | 100.98% |
| Biomind Labs Inc. | -1 Million USD | -3492.105% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -3793.792% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 144.307% |
| Nascent Biotech, Inc. | -2.22 Million USD | -1526.366% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 49.48% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 837.892% |
| GeneThera, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 1124.463% |
| Adynxx, Inc. | - USD | Infinity% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -2260.992% |
| Marizyme, Inc. | -34.08 Million USD | -6.394% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -334.323% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -6321.91% |
| Zenith Capital Corp. | -8.94 Million USD | -305.524% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -1172.265% |
| Halberd Corporation | -75.05 Thousand USD | -48222.452% |
| Genus plc | 6.4 Million USD | 666.656% |
| Pharming Group N.V. | -4.87 Million USD | -643.225% |
| MetaStat, Inc. | - USD | Infinity% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -1725.642% |
| IMV Inc. | -38.67 Million USD | 6.22% |
| Affymax, Inc. | -15.04 Million USD | -141.034% |
| SYBLEU INC | -149.18 Thousand USD | -24210.229% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -3373.755% |
| Enzolytics Inc. | -2.14 Million USD | -1587.733% |
| argenx SE | -425.04 Million USD | 91.468% |
| AVAX Technologies, Inc. | 6.69 Million USD | 641.859% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -2486.75% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -2615.678% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | -868.018% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -143984.227% |
| Cell Source, Inc. | -4.32 Million USD | -738.453% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -7407.525% |
| Q BioMed Inc. | -3.44 Million USD | -952.526% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -755.65% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -2787.42% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -1280.236% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -696.228% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 34.029% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -1150.013% |
| Rebus Holdings, Inc. | -664 Thousand USD | -5361.747% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -3585.371% |
| Skye Bioscience, Inc. | -13.67 Million USD | -165.261% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -1845.215% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -1708.997% |
| ONE Bio Corp. | 13.68 Million USD | 365.072% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -1776.53% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -3123.914% |
| Agentix Corp. | -1.37 Million USD | -2543.765% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -1142.223% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -2196.254% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -208074.043% |
| Kadimastem Ltd | -3.04 Million USD | -1092.862% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -13756.476% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -8628.72% |
| NovAccess Global Inc. | -2.46 Million USD | -1370.188% |
| Itoco Inc. | -919.14 Thousand USD | -3845.645% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -16378.703% |
| Qrons Inc. | -643.67 Thousand USD | -5534.192% |
| Mobile Lads Corp. | -554.55 Thousand USD | -6439.717% |
| Genscript Biotech Corporation | -415.79 Million USD | 91.278% |
| International Stem Cell Corporation | -663 Thousand USD | -5369.985% |
| Bioxytran, Inc. | -3.82 Million USD | -849.335% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -68794.377% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -178198.918% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -2141.409% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -4828.551% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -1065.734% |
| Neutra Corp. | -229.48 Thousand USD | -15703.143% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -106.773% |
| PureTech Health plc | -146.19 Million USD | 75.194% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | -68.749% |
| IXICO plc | -1.43 Million USD | -2423.73% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -282.109% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 70.226% |
| CSL Limited | 3.81 Billion USD | 100.951% |
| Cellectis S.A. | -108.85 Million USD | 66.685% |